

Synthesis of ethynyl-3-hydroxyquinoline-4-carboxylic acids

S. Yu. Maklakova,^{a*} A. D. Chuprov,^a M. P. Mazhuga,^a E. K. Beloglazkina,^a N. V. Zyk,^a and A. G. Majouga^{a,b,c}

^aDepartment of Chemistry, M. V. Lomonosov Moscow State University,
Build. 3, 1 Leninskie Gory, 119991 Moscow, Russian Federation.
E-mail: MaklakovaSU@yandex.ru

^bD. I. Mendeleev University of Chemical Technology of Russia,
9 Miusskaya pl., 125047 Moscow, Russian Federation

^cLaboratory of biomedical nanomaterials, National University of Science and Technology MISiS,
4 Leninskiy prosp., 119049 Moscow, Russian Federation


3-Hydroxyquinoline-4-carboxylic acids containing ethynyl moiety in the 6th and 8th positions were obtained for the first time. A synthetic approach to aforementioned compounds based on the Sonogashira cross-coupling and the Pfitzinger reaction was developed. Physicochemical properties of the newly synthesized structures were investigated.

Key words: 3-hydroxyquinoline-4-carboxylic acids, Sonogashira reaction, Pfitzinger reaction.

Currently, a number of quinoline-4-carboxylic acid derivatives with a hydroxyl group in position 3, which have biological activity (anti-inflammatory and anti-thrombotic), are known.^{1–3} At the same time, the methods for the synthesis of 3-hydroxyquinoline-4-carboxylic acids substituted with halogen, alkyl, and heteroaryl substituents in the positions 5–8 have been well studied,^{1–3} while their alkynyl analogs have not been described in the literature. In this regard, the purpose of this work was to develop a synthetic approaches to such compounds with a triple bond in positions 6 or 8.

The main step in the synthesis of target compounds was the Pfitzinger reaction.^{4,5} 1-(4-Chlorophenyl)-3-hydroxyprop-2-one (**1**) was used as a model carbonyl compound, which allowed us to introduce the hydroxyl group at position 3 of the quinoline. α -Hydroxyketone was prepared according to known procedure³ from 2-(chlorophenyl)acetyl chloride using 1,1,2-tris(trimethylsilyloxy)-ethylene to build up the carbon skeleton (Scheme 1).


Scheme 1



i, 1) 100 °C, 2) HCl, dioxane, Δ .

Sandmeyer reaction^{1,2} was used for the synthesis of halogenated isatin derivatives from the corresponding iodo-substituted anilines. Obtained isatins were introduced into Sonogashira reaction in the standard for this cross-coupling reaction conditions, namely, $\text{Pd}(\text{Ph}_3\text{P})_4$ and copper(I) iodide were used as catalysts (Scheme 2).

Scheme 2



Com- pound	R	Yield (%)	Com- pound	R'	Yield (%)
2	7-C $\equiv$ C-TMS	48	4	8-C $\equiv$ CH	16
3	5-C $\equiv$ C-TMS	22	5	6-C $\equiv$ CH	14

i, $\equiv$ —TMS, $\text{Pd}(\text{Ph}_3\text{P})_4$, CuI, Et_3N , DMF; *ii*. 1) **1**, KOH, H_2O —EtOH, 2) HCl.

Note that in the literature the synthesis of compound **2** is mentioned only once, while the authors managed to isolate the product in 5% yield (see Ref. 6). Physicochemical properties of isatins **2** and **3** were not described.

In our case, the yield of the target product of cross-coupling **2** was 48% and compounds **2** and **3** were characterized by a complex of physico-chemical methods of analysis.

In order to synthesize the target quinolines, α -hydroxyketone **1** was introduced into the Pfitzinger reaction with isatin **2** and **3** containing triple bonds (see Scheme 2). The trimethylsilyl group was removed under alkaline conditions. Therefore, no additional step was required to obtain a free terminal alkyne.

3-Hydroxyquinoline-4-carboxylic acids containing ethynyl moiety in positions 6 and 8, were obtained for the first time. Their composition was confirmed using high-resolution mass spectrometry, and their structures were confirmed by ^1H and ^{13}C NMR and IR spectroscopy.

Experimental

^1H and ^{13}C NMR spectra were registered using a Bruker Avance 400 spectrometer with working frequencies 400 and 100 MHz. High-resolution mass spectra were recorded using a Orbitrap Elite spectrometer (Thermo Fischer Scientific). The solutions of the samples in acetonitrile with the addition of 1% of formic acid were introduced into the ionization source by the electrospray method. IR spectra were recorded using an IR200 FTIR spectrometer (Thermo Nicolet, USA) with resolution of 4 cm^{-1} .

Synthesis of indoline-2,3-diones **2 and **3** (general procedure).** 5-Iodo- or 7-iodoisatin (550 mg, 2.0 mmol), $\text{Pd}(\text{PPh}_3)_4$ (50 mg, 0.04 mmol), CuI (40 mg, 0.2 mmol) were dissolved in DMF (5 mL), then Et_3N (700 μL , 5.0 mmol) was added, and the mixture was stirred under inert atmosphere (N_2) for 1 h. Trimethylsilylacetylene (430 μL , 3.0 mmol) was added and the reaction mixture was stirred at 80°C for 4 h, then cooled down, and filtered *via* Celite® layer. Then EtOAc was added, the mixture was washed with water and saturated NaCl solution, dried with Na_2SO_4 . The solvent was removed under reduced pressure, and product was purified by column chromatography (CHCl_3).

7-[(Trimethylsilyl)ethynyl]indoline-2,3-dione (2**).** Orange crystalline compound was obtained, the yield was 236 mg (48%), m.p. $189\text{--}190^\circ\text{C}$. IR (CDCl_3), ν/cm^{-1} : 3181 (N—H); 2166 (C $\equiv$ C); 1747 (overlapping contour of two C=O). ^1H NMR (CDCl_3), δ : 8.31 (br.s, 1 H, NH); 7.60 (dd, 1 H, H_{arom} , $J = 7.8\text{ Hz}$, $J = 1.2\text{ Hz}$); 7.56 (d, 1 H, H_{arom} , $J = 7.5\text{ Hz}$); 7.08 (t, 1 H, H_{arom} , $J = 7.7\text{ Hz}$); 0.30 (s, 9 H, $\text{Si}(\text{CH}_3)_3$). ^{13}C NMR (DMSO-d_6), δ : 183.7, 159.9, 152.0, 140.0, 131.4, 124.9, 122.7, 118.3, 106.7, 98.0, -0.2 . MS: found m/z 242.0633 [$\text{M} - \text{H}$] $^-$; $\text{C}_{13}\text{H}_{12}\text{NO}_2\text{Si}$; calculated: 242.0643.

5-[(Trimethylsilyl)ethynyl]indoline-2,3-dione (3**).** Orange crystalline compound was obtained, the yield was 108 mg (22%), m.p. $216\text{--}218^\circ\text{C}$. IR (CDCl_3), ν/cm^{-1} : 3222 (N—H); 2150 (C $\equiv$ C); 1763, 1745 (C=O). ^1H NMR (CDCl_3), δ : 8.04 (br.s, 1 H, NH); 7.72 (d, 1 H, H_{arom} , $J = 1.7\text{ Hz}$); 7.66 (dd, 1 H, H_{arom} , $J = 8.2\text{ Hz}$, $J = 1.7\text{ Hz}$); 6.88 (d, 1 H, H_{arom} , $J = 8.2\text{ Hz}$); 0.26 (s, 9 H, $\text{Si}(\text{CH}_3)_3$). ^{13}C NMR ($\text{CDCl}_3 + \text{CD}_3\text{OD}$), δ : 183.3, 159.3, 149.8, 141.5, 128.3, 118.2, 117.3, 112.2, 102.7, 94.6, -0.65 . MS: found m/z 242.0643 [$\text{M} - \text{H}$] $^-$; $\text{C}_{13}\text{H}_{12}\text{NO}_2\text{Si}$; calculated: 242.0643.

Synthesis of 3-hydroxyquinoline-4-carboxylic acids **4 and **5** (general procedure).** The corresponding indolin-2,3-dione (75 mg, 0.30 mmol) in 6 M KOH aqueous solution (2 mL) was placed in a two-neck round-bottomed flask equipped with a reflux condenser and heated to 100°C . 3-(4-Chlorophenyl)-

1-hydroxypropan-2-one (**1**) (65 mg, 0.35 mmol) was dissolved in ethanol (2 mL) and added in two portions to the solution. The reaction mixture was heated to reflux for 4 h, then cooled down to room temperature, and the solvents were removed under reduced pressure. The residue was dissolved in water and filtered. The filtrate was acidified to pH 1 with 1 M HCl solution. The precipitate was filtered and washed with water. Purification was performed using column chromatography ($\text{EtOAc}-\text{CH}_3\text{CN}-\text{MeOH}$, 70/5/2.5 + 0.5% Et_3N , v/v). The isolated fraction was dissolved in acetonitrile—water mixture, 1 M HCl solution was added to pH 1, and the product was collected by filtration, washed with water, and dried.

2-(4-Chlorobenzyl)-8-ethynyl-3-hydroxyquinoline-4-carboxylic acid (4**).** Brown crystalline compound was obtained, the yield was 16 mg (16%), m.p. $110\text{--}112^\circ\text{C}$. IR (KBr), ν/cm^{-1} : 3560 (O—H); 3276 ($\text{C}\equiv\text{H}$); 1658 (C=O). ^1H NMR (DMSO-d_6), δ : 8.58 (d, 1 H, H_{arom} , $J = 8.6\text{ Hz}$); 7.73 (d, 1 H, H_{arom} , $J = 7.4\text{ Hz}$); 7.53 (td, 1 H, H_{arom} , $J = 8.6\text{ Hz}$, $J = 2.0\text{ Hz}$); 7.32 (s, 4 H, H_{arom}); 4.41 (s, 1 H, C $\equiv$ CH); 4.30 (s, 2 H, CH_2). ^{13}C NMR (DMSO-d_6), δ : 171.2, 155.5, 152.5, 141.8, 137.7, 131.5, 131.3, 131.2, 128.7, 127.7, 125.9, 125.4, 122.2, 115.2, 86.3, 82.3, 38.9. MS: found m/z 336.0430 [$\text{M} - \text{H}$] $^-$; $\text{C}_{19}\text{H}_{11}\text{ClNO}_3$; calculated: 336.0433.

2-(4-Chlorobenzyl)-6-ethynyl-3-hydroxyquinoline-4-carboxylic acid (5**).** Brown crystalline compound was obtained, the yield was 14 mg (14%). IR (KBr), ν/cm^{-1} : 3298 (O—H); 2917 ($\text{C}\equiv\text{H}$); 1658 (C=O). ^1H NMR (DMSO-d_6), δ : 8.87 (s, 1 H, H_{arom}); 7.90 (d, 1 H, H_{arom} , $J = 8.6\text{ Hz}$); 7.56 (dd, 1 H, H_{arom} , $J = 8.6\text{ Hz}$, $J = 1.7\text{ Hz}$); 7.33 (s, 4 H, H_{arom}); 4.34 (s, 1 H, C $\equiv$ CH); 4.32 (s, 2 H, CH_2). ^{13}C NMR (DMSO-d_6), δ : 171.2, 156.4, 151.8, 141.5, 137.3, 131.5, 131.3, 129.1, 128.9, 128.8, 128.7, 124.3, 121.4, 111.7, 84.2, 82.3, 38.4. MS: found m/z 336.0436 [$\text{M} - \text{H}$] $^-$; $\text{C}_{19}\text{H}_{11}\text{ClNO}_3$; calculated: 336.0433.

The work was financially supported by the Russian Foundation for Basic Research (Project No. 18-33-01237\18). The authors are grateful to Thermo Fisher Scientific, Inc., MS Analytics (Moscow), and to Professor A. A. Makarov for providing the equipment used in this work.

References

1. N. Kaila, K. Janz, A. Huang, A. Moretto, S. DeBernardo, P. W. Bedard, S. Tam, V. Clerin, J. C. Keith, D. H. H. Tsao, N. Sushkova, G. D. Shaw, R. T. Camphausen, R. G. Schaub, Q. Wang, *J. Med. Chem.*, 2007, **50**, 40.
2. N. Kaila, K. Janz, S. DeBernardo, P. W. Bedard, R. T. Camphausen, S. Tam, D. H. H. Tsao, J. C. Keith, C. Nickerson-Nutter, A. Shilling, R. Young-Sciame, Q. Wang, *J. Med. Chem.*, 2007, **50**, 21.
3. A. Huang, A. Moretto, K. Janz, M. Lowe, P. W. Bedard, S. Tam, L. Di, V. Clerin, N. Sushkova, B. Tchernychev, D. H. H. Tsao, J. C. Keith, G. D. Shaw, R. G. Schaub, Q. Wang, N. Kaila, *J. Med. Chem.*, 2010, **53**, 6003.
4. M. G. A. Shvakhgeimer, *Chem. Heterocycl. Compd.*, 2004, **40**, 257.
5. V. V. Melyshenkova, D. N. Kuznetsov, A. G. Ruchkina, K. I. Kobrakov, *Russ. Chem. Bull.*, 2018, **67**, 878.
6. M. K. Uddin, S. G. Reignier, T. Coulter, C. Montalbetti, C. Gr  n  s, S. Butcher, C. Krog-Jensen, J. Felding, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 2854.

Received December 31, 2018;
in revised form April 12, 2019;
accepted April 18, 2019